glp-1 drugs and pcos Liraglutide polycystic ovary syndrome: is it only a matter of body weight? | Journal of Endocrinological Investigation GLP-1 agonists and PCOS weight
Description
GLP-1 receptor activation leads to increased cAMP, which inhibits the signaling pathways downstream of these ADP receptors, thereby reducing platelet activation [92]
doi:10.1016/j.clinthera.2011.04.024 123
GLP-1 RAs did not improve the change in LVEF (mean difference [MD]): 0.86, p = 0.12, left-ventricular end-diastolic volume (LVEDV) (MD: 3.54, p = 0.11), left-ventricular end-systolic volume (LVESV) (MD: 2.78, p = 0.07) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) (MD: 140.36, p = 0.08)
This is because the cells havent specialized into different organs yettheyre just a tiny cluster of identical cells
As weight is lost, the body adapts (metabolically) and requires fewer calories to support a lower weight, Dawkins says
